As overall survival in myeloma continues to increase, there is an opportunity to improve outcomes further with nutrition and lifestyle interventions and this can no longer be ignored. In this IMF Living Well With Myeloma Webinar, Dr. Shah discusses the scientific evidence behind dietary guidance for cancer and myeloma - epidemiologic studies and clinical trials such as the NUTRIVENTION trials through which diet may affect cancer via the microbiome, metabolism, and the immune system. The talk concludes with some practical tips and suggestions to improve dietary habits.
What to Expect
As overall survival in myeloma continues to increase, there is an opportunity to improve outcomes further with nutrition and lifestyle interventions and this can no longer be ignored.
Join Dr. Shah as she discusses the scientific evidence behind dietary guidance for cancer and myeloma—epidemiologic and clinical trials such as the NUTRIVENTION trials through which diet may affect cancer via the microbiome, metabolism, and the immune system. The webinar will conclude with some practical tips and suggestions to improve dietary habits.
The Living Well with Myeloma Webinar will conclude with a summary discussion and a Live Q&A. At the end of the presentations, attendees will have time to ask questions.
We look forward to your active participation in this LIVE webinar. Be engaged and empowered!
Speaker:
Urvi A. Shah, MD, is an Assistant Attending in Myeloma Service at Memorial Sloan Kettering Cancer Center (MSK) and an Assistant Professor of Medicine at Weill Cornell Medicine. She completed fellowships in hematology/oncology at Montefiore Medical Center, and in cancer immunotherapy at MSK and the Parker Institute for Cancer Immunotherapy in New York. She is board certified in Internal Medicine, Hematology and Medical Oncology.
Dr. Shah’s clinical practice includes all plasma cell disorders. Her research interests include modifiable risk factors (diet, metabolism, and the microbiome) and immune therapies. She opened the first pilot nutrition trial in plasma cell disorders to date (NUTRIVENTION; NCT04920084) in 2021 that completed enrollment. Dr. Shah has three other NUTRIVENTION/immune therapy investigator-initiated trials (NCT05640843, NCT04497961, NCT04174196) currently enrolling.
Dr. Shah has been supported by career development awards from the National Cancer Institute Paul Calabresi K12, International Myeloma Society and American Society of Hematology Scholar Award. She is currently pursuing a master's in science degree through the Gerstner Sloan Kettering Graduate School of Biomedical Sciences. Dr. Shah has published first author papers in prominent journals such as Blood and Clinical Cancer Research, among others. She has been an invited speaker and session chair nationally and internationally.
Webinar Sponsors:
With Support From: Bristol Myers Squibb, Janssen, Karyopharm, and Sanofi
